Delving into the Latest Updates on LY-3537021 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

GIPR Agonist LA (Eli Lilly and Company)

Target

GIPR

Action

agonists

Mechanism

GIPR agonists(Gastric inhibitory polypeptide receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Eli Lilly & Co.

Active Organization

Eli Lilly & Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.

Start Date08 Aug 2022

Sponsor / Collaborator

Eli Lilly & Co.

NCT04586907

/ CompletedPhase 1

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus

The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it.
This study will last up to about 19 weeks including screening period.

Start Date23 Nov 2020

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with LY-3537021

Login to view more data

100 Translational Medicine associated with LY-3537021

Login to view more data

100 Patents (Medical) associated with LY-3537021

Login to view more data

100 Deals associated with LY-3537021

Login to view more data